FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100642235> ?p ?o ?g. }

• W2100642235 endingPage "S5" @default.
• W2100642235 startingPage "S5" @default.
• W2100642235 abstract "Opioids are effective at managing moderate to severe pain; however, several liabilities are associated with their use including abuse potential and risk for dependence. Detecting abuse signals early on can guide future clinical development and influence trial design around the understanding of those liabilities. One approach involves collecting abuse-related AEs in studies with recreational opioid users, who are particularly sensitive to positive opioid effects. This analysis explores the potential for AEs to signal abuse and other liabilities early on. Adverse Event and PD data for opioids were obtained from single-dose, randomized, double-blind crossover studies in recreational opioid users (8 Studies; N=185). Opioids included Hydromorphone (4, 8, 16mg); Hydrocodone 60 mg; Morphine 120mg; Oxymorphone 15 and 30mg; Oxycodone 30, 40, and 60mg3; and intravenous Hydromorphone 30μg/kg and Oxycodone 0.07mg/kg. AEs were coded and categorized as Actual Abuse/Dependence [AD] and those suggestive of Mood-Elevating (ME) or Sedative (SED) effects. Percentage of AE incidence (% of subjects) across treatments was summarized and correlations between PD measures and AEs were performed. No AD adverse events were reported in >750 exposures. The highest incidence of ME events was observed with oxycodone (50%) followed by hydromorphone (∼25%). Sedative effects were reported less often than ME effects. The highest incidence of sedative effects was reported in oxycodone (∼45%) followed by placebo (24%) and oxymorphone (∼21%). Across opioids, the most common ME event was ‘euphoric mood', and ‘somnolence’ was the most common SED event. Drug Liking/Overall Drug Liking scores were higher in subjects who reported euphoric mood as an AE. There was a significant correlation (p<0.001) between median Drug Liking/Overall Drug Liking scores and euphoric mood AE incidence. This evaluation indicated that AEs were generally consistent with PD results suggesting that clinical trial AE patterns may be useful for detecting abuse liability in early drug development. Opioids are effective at managing moderate to severe pain; however, several liabilities are associated with their use including abuse potential and risk for dependence. Detecting abuse signals early on can guide future clinical development and influence trial design around the understanding of those liabilities. One approach involves collecting abuse-related AEs in studies with recreational opioid users, who are particularly sensitive to positive opioid effects. This analysis explores the potential for AEs to signal abuse and other liabilities early on. Adverse Event and PD data for opioids were obtained from single-dose, randomized, double-blind crossover studies in recreational opioid users (8 Studies; N=185). Opioids included Hydromorphone (4, 8, 16mg); Hydrocodone 60 mg; Morphine 120mg; Oxymorphone 15 and 30mg; Oxycodone 30, 40, and 60mg3; and intravenous Hydromorphone 30μg/kg and Oxycodone 0.07mg/kg. AEs were coded and categorized as Actual Abuse/Dependence [AD] and those suggestive of Mood-Elevating (ME) or Sedative (SED) effects. Percentage of AE incidence (% of subjects) across treatments was summarized and correlations between PD measures and AEs were performed. No AD adverse events were reported in >750 exposures. The highest incidence of ME events was observed with oxycodone (50%) followed by hydromorphone (∼25%). Sedative effects were reported less often than ME effects. The highest incidence of sedative effects was reported in oxycodone (∼45%) followed by placebo (24%) and oxymorphone (∼21%). Across opioids, the most common ME event was ‘euphoric mood', and ‘somnolence’ was the most common SED event. Drug Liking/Overall Drug Liking scores were higher in subjects who reported euphoric mood as an AE. There was a significant correlation (p<0.001) between median Drug Liking/Overall Drug Liking scores and euphoric mood AE incidence. This evaluation indicated that AEs were generally consistent with PD results suggesting that clinical trial AE patterns may be useful for detecting abuse liability in early drug development." @default.
• W2100642235 created "2016-06-24" @default.
• W2100642235 creator A5002986623 @default.
• W2100642235 creator A5063835119 @default.
• W2100642235 date "2013-04-01" @default.
• W2100642235 modified "2023-10-05" @default.
• W2100642235 title "Opioid related adverse events in clinical trials- indicators for abuse liability" @default.
• W2100642235 doi "https://doi.org/10.1016/j.jpain.2013.01.030" @default.
• W2100642235 hasPublicationYear "2013" @default.
• W2100642235 type Work @default.
• W2100642235 sameAs 2100642235 @default.
• W2100642235 citedByCount "0" @default.
• W2100642235 crossrefType "journal-article" @default.
• W2100642235 hasAuthorship W2100642235A5002986623 @default.
• W2100642235 hasAuthorship W2100642235A5063835119 @default.
• W2100642235 hasBestOaLocation W21006422351 @default.
• W2100642235 hasConcept C126322002 @default.
• W2100642235 hasConcept C170493617 @default.
• W2100642235 hasConcept C197934379 @default.
• W2100642235 hasConcept C2776029756 @default.
• W2100642235 hasConcept C2776316548 @default.
• W2100642235 hasConcept C2776389719 @default.
• W2100642235 hasConcept C2779158186 @default.
• W2100642235 hasConcept C2781063702 @default.
• W2100642235 hasConcept C42219234 @default.
• W2100642235 hasConcept C71924100 @default.
• W2100642235 hasConceptScore W2100642235C126322002 @default.
• W2100642235 hasConceptScore W2100642235C170493617 @default.
• W2100642235 hasConceptScore W2100642235C197934379 @default.
• W2100642235 hasConceptScore W2100642235C2776029756 @default.
• W2100642235 hasConceptScore W2100642235C2776316548 @default.
• W2100642235 hasConceptScore W2100642235C2776389719 @default.
• W2100642235 hasConceptScore W2100642235C2779158186 @default.
• W2100642235 hasConceptScore W2100642235C2781063702 @default.
• W2100642235 hasConceptScore W2100642235C42219234 @default.
• W2100642235 hasConceptScore W2100642235C71924100 @default.
• W2100642235 hasIssue "4" @default.
• W2100642235 hasLocation W21006422351 @default.
• W2100642235 hasOpenAccess W2100642235 @default.
• W2100642235 hasPrimaryLocation W21006422351 @default.
• W2100642235 hasRelatedWork W1922363525 @default.
• W2100642235 hasRelatedWork W1992209480 @default.
• W2100642235 hasRelatedWork W2095755089 @default.
• W2100642235 hasRelatedWork W2115320588 @default.
• W2100642235 hasRelatedWork W2891297835 @default.
• W2100642235 hasRelatedWork W2941629973 @default.
• W2100642235 hasRelatedWork W2977187351 @default.
• W2100642235 hasRelatedWork W2993766263 @default.
• W2100642235 hasRelatedWork W4308649041 @default.
• W2100642235 hasRelatedWork W4311694118 @default.
• W2100642235 hasVolume "14" @default.
• W2100642235 isParatext "false" @default.
• W2100642235 isRetracted "false" @default.
• W2100642235 magId "2100642235" @default.
• W2100642235 workType "article" @default.